Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2026-05-26 @ 12:03 AM
Study NCT ID:
NCT05973903
Status:
WITHDRAWN
Last Update Posted:
2024-12-04
First Post:
2023-07-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Sponsor:
Tel Aviv Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
0489-22 TLV
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None